MET and cancer: Its deregulated expression and activation, resulting from MET receptor dimerization and tyrosine autophosphorylation on Y1234/5, have been associated with the onset and progression of several types of cancer and thus led to a great interest in the development of MET-targeting therapeutic compounds [10, 11].